{
  "docId": "019de071-d756-7568-8588-410684bab010",
  "docSlug": "c18c99fc10f671fc397f8a743cdc0ce4",
  "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 23 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 23,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-d756-7568-8588-410684bab010/18",
  "deckHref": "/decks/019de071-d756-7568-8588-410684bab010",
  "deckJsonHref": "/decks/019de071-d756-7568-8588-410684bab010.json",
  "deckAnchorHref": "/decks/019de071-d756-7568-8588-410684bab010#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.43,
        "x": 0.51,
        "y": 0.0025
      },
      "kind": "chart",
      "text": "Estimated Prevalence of >2,500 Patients in Key Global Markets",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9546e87-90c8-4180-b1e1-ebc1cb45ff08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.43,
        "x": 0.51,
        "y": 0.7
      },
      "kind": "legend",
      "text": "United States >250 patients; Western Europe and Middle East >900 patients; Rest of World >1,350 patients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "282db519-5799-4aad-b9e1-9492456f0cba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.41,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "list",
      "text": "Severe and progressive disease with early mortality; Easily diagnosed but often missed due to lack of awareness; Standard of care provides poor control of plasma arginine levels; No approved therapies to address high arginine levels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d1f6f03-a178-4f21-9f89-c70c5139a42c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.43,
        "x": 0.06,
        "y": 1
      },
      "kind": "paragraph",
      "text": "Significant Unmet Need",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c14f85a6-1805-486e-9515-de628d5fe3c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Licensing and supply agreement signed with Immedica Pharma AB in March 2021; countries in agreement include European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain and Oman.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0189dccc-8853-493a-a55e-2434a780792f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Attractive Commercial Opportunity for Pegzilarginase in ARG1-D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bbc7cf6-7444-4e29-9bdd-c0517878cdb3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 17,
      "beatId": "a86c9ca1-cc85-479e-8c1a-21e60e6a73da",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides emphasize the impact of unmanaged arginine levels on patients.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4c241dda-0f46-4b49-a593-48cefd4422b6",
      "evidence": "Emphasizes the need for a solution by highlighting current limitations.",
      "position": 0,
      "objective": "Highlights the cost of not addressing ARG1-D effectively",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}